The biotechnology sector is trading higher in the pre-market, driven by strong quarterly results and increased full-year guidance from industry heavyweight Amgen. This positive momentum is further supported by a report from the International Biotechnology Trust highlighting significant returns driven by a surge in M&A activity, a trend expected to continue. A collection of other positive company-specific news, including earnings beats and analyst upgrades, is also contributing to the broad-based gains.